[ad_1]
ABU DHABI, 10th January, 2023 (WAM) — Mubadala Investment Company PJSC (Mubadala), Abu Dhabi’s sovereign investor, and National Resilience, Inc. (Resilience), a technology-enabled manufacturing company focused on expanding access to complex medicines , has signed an agreement to further advance the UAE’s life sciences ecosystem through biopharmaceutical manufacturing.
Through a development agreement, Mubadala will establish a new manufacturing facility and Resilience will operate and manufacture biopharmaceutical-related products outside of the United Arab Emirates.
The therapeutic range will address complex diseases such as cancer, infectious diseases, inflammation and autoimmune diseases.
The facility in Abu Dhabi will be the first Good Manufacturing Practice (GMP) biopharmaceutical facility in the UAE and the first of its kind in the region to produce essential life science products for advanced biologics.
In the past two years, Mubadala has conducted multiple rounds of equity financing for Resilience.
Both parties will leverage their respective strengths to achieve a common goal of success. As a strategic investor focused on accelerating the diversification of the UAE’s economy through innovative investments, Mubadala will leverage the existing capabilities of its portfolio companies; Strata Manufacturing (Strata), currently an advanced manufacturing champion in the manufacture of complex parts for the aerospace sector.
In addition, Mubadala will also seek to strengthen the UAE’s life sciences ecosystem by leveraging UAE initiatives such as the HOPE Consortium, an Abu Dhabi-led partnership that operates the largest and most complete terminal One of the end pharmaceutical supply chains today.
At the forefront of the UAE’s healthcare industry, Mubadala is driving the development of the country’s life sciences sector by fostering innovation and partnerships to build national capacity and strengthen national drug security to further enhance biopharmaceutical manufacturing capabilities, which will benefit from Fundamentally benefit the entire country.
The agreement with Resilience builds on Mubadala’s decade of world-class patient care and its breakthrough health and wellness solutions. The partnership with Resilience also follows the recent announcement that Mubadala Health and G42 Healthcare have teamed up to form a new, first-of-its-kind integrated healthcare technology company poised to revolutionize the regional healthcare landscape and deliver a new approach to personalized, patient-centric center care.
The agreement was witnessed by Mubadala UAE Investment Company CEO Musabbeh Al-Kaabi and signed by Badr Al-Olama, Executive Director, Mubadala UAE Cluster, and Rahul Singhvi, ScD, CEO, Resilience.
Commenting on the agreement, Badr Al-Olama Executive Director, Mubadala’s UAE investment platform, Badr Al-Olama, said: “We are actively investing in innovation and firmly believe that by strengthening Abu Dhabi’s national life sciences ecosystem, we will “Building a future-focused, sustainable and knowledge-based economy for the UAE. Through this agreement, Mubadala and its group of companies will unlock further growth opportunities within the life sciences ecosystem and partner with our key Together with our partners, we will play an important role in establishing a state-of-the-art biopharmaceutical park to ensure that supply in the region comes from Abu Dhabi-based chains.”
“We are excited to expand the footprint of our Resilience manufacturing network beyond North America. This is an important milestone, not only for our company but for our country,” said Rahul Singhvi, Sc.D., CEO of Resilience . “We look forward to working with U.S. allies in the region to ensure access to trusted, cutting-edge biopharmaceutical manufacturing capabilities to support local, regional and global economies.”
National Resilience, a well-known biotechnology company headquartered in California, USA, is building a network of high-tech, end-to-end manufacturing solutions designed to ensure the rapid and safe fulfillment of existing and future needs and scale of complex drugs.
The US-based company will provide manufacturing, technical and operational expertise at the Abu Dhabi facility, integrating it as a node in a global network of facilities.
This partnership is in line with the UAE’s industrial strategy, which identifies life sciences as a priority sector.
Under the strategy, the UAE is inviting investors, industrialists and companies to set up business in the country and benefit from its tremendous growth.
In the wake of the global COVID-19 pandemic, the life sciences industry has emerged as one of the fastest growing industries globally and a priority investment area for private equity and venture capital.
The global life sciences products market is estimated to be worth around USD 5 billion by the end of 2027.
Recognizing this high growth rate and the growing biopharmaceutical supply shortage globally, countries are actively supporting biopharmaceutical manufacturing capabilities and the UAE has been a powerhouse in this journey of developing world-class national healthcare capabilities across the life sciences supply chain. . Through the agreement, biopharmaceutical manufacturing can provide advanced patient care services.
[ad_2]
Source link